TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06643130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JW0104+C2402
Description: For 8 weeks(PO (Per Oral), QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JW0104+C2403
Description: For 8 weeks(PO, QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C2402
Description: For 8 weeks(PO, QD)
Study: NCT06645301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled
Study: NCT06644547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gezond en goed met elkaar
Description: The intervention 'Gezond en goed met elkaar' focuses on improving (positive) health literacy and literacy. The six domains of positive health are the focus of the intervention meetings. This intervention has been made available for citizens of Almere, Zwolle, Gouda, Nunspeet and Leusden through collaboration with these municipalities. Lifestyle coaches working in these municipalities implement the intervention.
Study: NCT04416815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrating Health promotion with and for Older People - eHealth
Description: The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
Study: NCT04287829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsule
Study: NCT06232993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal Splinting
Description: Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
Study: NCT05837897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vedolizumab placebo-matching IV infusion
Study: NCT04543786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
Study: NCT06082843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching Avenciguat (BI 685509)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)
Study: NCT06636110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jun mHealth app
Description: The intervention will be a mHealth app, JUN, across 3 months during pregnancy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jun mHealth app
Description: The intervention will be a mHealth app, JUN, across 3 months during pregnancy.
Study: NCT06635122

Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.

Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.

Intervention type: PROCEDURE
Intervention: Endoscopic treatment
Description: Endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic variceal histoacryl injection therapy , or a combination of several methods were selected according to the location, size, and shape of the patient's varicose veins.Treatment failure can be transferred to TIPS therapy.
Study: NCT06313866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control
Description: Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control
Description: Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control
Description: Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronuchal acupuncture group treatment
Description: Electronuchal acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell therapy group treatment
Description: nasal suction intervention with volatile oil of Acorus calamus

Intervention type: OTHER
Group type: OTHER
Intervention: Smell therapy group treatment
Description: nasal suction intervention with volatile oil of Acorus calamus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronuchal acupuncture combined with smell and inhalation therapy group treatment
Description: On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
Study: NCT05830097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1019
Description: Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
Study: NCT05383898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Study: NCT04874610

Intervention type: DRUG
Intervention: Methylprednisolone
Description: Administration of methylprednisolone Prescribed per Standard of care

Intervention type: DRUG
Intervention: Methylprednisolone
Description: Administration of methylprednisolone Prescribed per Standard of care
Study: NCT05378581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality mask
Description: virtual reality mask Deepsen® with age-appropriate software Birdy®
Study: NCT06275971

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG or venous/arterial blood glucose
Description: Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
Study: NCT06253312

Intervention type: PROCEDURE
Intervention: Open surgery
Description: Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass

Intervention type: PROCEDURE
Intervention: Hybrid repair
Description: Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis

Intervention type: PROCEDURE
Intervention: Endovascular repair
Description: Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
Study: NCT05378581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control arm
Description: usual process
Study: NCT04598087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically \~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
Study: NCT04858256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib will be dosed at 200mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib will be dosed at 200mg twice daily.
Study: NCT06409195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-020 1% Gel
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-020 1% Gel
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-020 1% Gel
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-020 1% Gel
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-020 1% Gel
Description: SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
Study: NCT05909943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
Study: NCT05066451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: %5 dextrose prolotherapy
Description: Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: %15 dextrose prolotherapy
Description: Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact.
Study: NCT04845347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dim Light Therapy
Description: Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
Study: NCT06030856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STI test kits (NG, CT and TV) for home use
Description: The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Administered Behavioural Risk Assessment
Description: Self Administered assessment to determine risk of HIV, STIs and pregnancy
Study: NCT06058559

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower lecithin
Description: Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Extra virgin olive oil
Study: NCT04363177

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based psychosocial peer-to-peer support
Description: The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based psychosocial peer-to-peer support
Description: The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting.
Study: NCT05517551

Intervention type: PROCEDURE
Intervention: robotic assisted radical prostatectomy
Description: Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery

Intervention type: PROCEDURE
Intervention: robotic assisted radical prostatectomy
Description: Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
Study: NCT06434818

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)
Description: EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CBOT with olfactory stimulants & OFC tasks
Description: The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: CBOT Sham
Description: CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks
Study: NCT06218368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational toolkit on MMR and polio vaccination
Description: The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
Study: NCT04229979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S
Description: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: injection
Study: NCT06030856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Administered Behavioural Risk Assessment
Description: Self Administered assessment to determine risk of HIV, STIs and pregnancy
Study: NCT06260501

Intervention type: OTHER
Intervention: super-wet technique
Description: Liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter
Study: NCT04229979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: palliative management

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Description: adjuvant
Study: NCT05155527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: 6 mg/tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo has same form as Ivermectin.
Study: NCT06416722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-Motor Dual Task Activities
Description: Patients included in this group will be given additional cognitive tasks (e.g. counting months, subtracting 5 from 100) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor-Motor Dual Task Activities
Description: Patients included in this group will be given additional motor tasks (e.g. passing the ball from the right hand to the left hand while standing on a soft surface, clapping) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-Motor & Motor-Motor Dual Task Activities
Description: Simultaneously with balance and large amplitude functional activities (such as stepping forwards-sideways-backwards, sitting and standing), patients included in this group will be given additional cognitive (e.g. counting while standing with feet closed) and motor (e.g. passing the ball from the right hand to the left hand while standing on a soft surface) tasks in accordance with the physiotherapist's commands.